Celldex Therapeutics' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Celldex Therapeutics, Inc. (CLDX)

Q2 2012 Earnings Call

August 10, 2012, 08:30 am ET

Executives

Anthony Marucci - President & CEO

Chip Catlin - SVP & CFO

Tom Davis - SVP & Chief Medical Officer

Tibor Keler - SVP & Chief Scientific Officer

Analysts

Jonathan Aschoff - Brean Murray

Mara Goldstein - Cantor Fitzgerald

Biren Amin - Jefferies

Joe Pantginis - Roth Capital Partners

Mani Mohindru - ThinkEquity

Steve Brozak - WBB Securities

Presentation

Operator

Good morning and welcome to Celldex Therapeutics second quarter and 2012 update conference call. My name is Chanel and I will be your operator on today's call.

Before we begin our discussion, I have been asked to caution listeners that today's speakers will be making forward-looking statements. Such statements reflect current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

Certain of the factors that might cause Celldex’s actual results to differ materially from those in the forward-looking statements include those set forth under the heading Risk Factors and management’s discussion and analysis of financial condition and results of operations and Celldex’s annual report on Form 10-K quarterly reports on Form 10-Q and its current report on Form 8-K as well as those described in Celldex’s press release and filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in the entirety by this cautionary notice. You should carefully review all these factors and be aware that there maybe other factors that could cause these differences. These forward-looking statements are based on information, plans and estimates as of this call and Celldex does not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other things.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today